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Summary It has been generally accepted that transforming growth factor 31 (TGF-j1l) has both negative and positive effects on tumour
growth and progression. This study analysed the prognostic value of TGF-1l mRNA in advanced gastric carcinoma. A reverse
transcriptase-polymerase chain reaction analysis (RT-PCR) was used forTGF-J1 in endoscopic biopsy specimens from 42 advanced gastric
carcinomas. Thirty specimens expressed TGF-p1 mRNA while 12 specimens did not. The follow-up duration ranged from 4 to 37 months
(mean 22.8 months). TGF-31-positive group demonstrated a shorter overall survival compared with theTGF-p1-negative group (P= 0.0014).
A significant correlation was also found in the 32 patients who underwent curative resection (P = 0.0048). Significant correlations were found
between TGF-41 mRNA expression and both stage (P= 0.0015) and nodal involvement (P= 0.0060). Multivariate analysis demonstrated that
only TGF-31 mRNA expression (P = 0.0306) was an independent prognostic factor. All of ten patients who underwent non-curative resection
expressed TGF-41 mRNA. Expression of TGF-I1 mRNA in gastric biopsy specimens may be an important preoperative prognostic variable
for advanced gastric carcinoma.
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It has been suggested that adxanced oastric carcinomas may be
dix-ided into poor and good prognostic groups. Recent studies of
Various types of tumours hax-e stronglx suggested that the malig-
nant potential of tumours can be correlated with gene expression
(Tahara et al. 1986). Here. we focused on the preoperative evalua-
tion of the malignant potential of gastric carcinoma related to
mRNA expression of tumour growth-related factors at the tumour
site (Nakamura et al. 1997). In advanced cases. mRnNA expression
for transformin,growth factor-Pl (TGF-P11) showxed a significant
positive correlation with nodal involvement (Nakamura et al.
1997). Traditional clinicopatholocical studies have show-n that
l-mph node involxement is an important risk factor for predictinc
overall survixal (Maruvrama et al. 1989: Jatzko et al. 1995). These
obserxations suggest that TGF- 1 mRNA expression in biopsy
specimens may identify a subgroup of gastric carcinoma patients
with verx acgressive disease.
TGF-3 has a dimeric structure with a molecular weight of
25 kDa (Assoian et al. 1983). It has been demonstrated that there
are three forms in humans: TGF-,B1. TGF-12 and TGF-13. with
TGF-,13 beincg the most prevalent (Miyazono et al. 1988). TGF-,B1
is a potent inhibitor of epithelial cell growth (Masui et al. 1986:
Shipley et al. 1986: Coffey et al. 1988: Moses et al. 1990).
How-ever. carcinoma cells. unlike normal cells. can escape from
neg,ative reaulation by TGF-PI at the post-transcriptional (Fow-lis
et al. 1992: Cui et al. 1994). receptor (Kimichiet al. 1988). or post-
Received28 October 1997
Revised27January 1998
Accepted 5 February 1998
Correspondence to: M Katano, Department of Surgery. Saga Medical School.
5-1-1 Nabeshima. Saga 849. Japan
receptor lexvel (Braun et al. 1990: Laiho et al. 1990: Pietenpol et al.
1990: Ito et al. 1992). Cui et al (1994) have suggested that highly
malignant carcinomas. especially advanced cases. may not be
inhibited by TGF-p1. and post-transcriptional down-regulation of
TGF-J1 production may enhance tumour growth. They have also
sugaested that once tumour cells are refractorx to grow-th regula-
tion. TGF-11 expression may confer a selectixe advantage to the
tumour bv enhancing angiogenesis or modulating stromal charac-
teristics or the immune response to tumourgrowth. thus leading to
increased invasion and metastasis (Torre-Amione et al. 1990:
Welch et al. 1990). On the basis ofthese previous data. we hypoth-
esized that TGF-,13 expression at the site of carcinoma. especially
advanced tumours. may contribute to highlx malignant behaviour.
MATERIALS AND METHODS
Patients and biopsy samples
Tumour biopsy specimens A-ere obtained dungn preoperative
endoscopy of 77 patients w-ith gastric carcinoma. As none of the
35 early-stage patients died during the follow-up period. these
A-ere excluded from this study. For--two patients with adx anced-
staae grastric carcinomas underxent resection at the Department of
Surgery. Saga Medical School. between 1993 and 1995. All 42
primary gastric carcinoma surgical specimens were classified
histologically usingr Japanese Classification of Gastric Carcinoma
(Japanese Research Society for Gastric Cancer. 1995). According
to this classification. tl. t2. t3 and t4 correspond to tumour inva-
sion ofthe mucosa or submucosa. muscularis propria or subserosa.
the serosa without invasion of adjacent structures and serosa with
adjacent structures respectively. Adx anced gastric carcinomas
consisted oft2. t3 and t4 specimens.
13731374 M Nakamura et al
TGF-1-positive cases
1 2 3 4 5 6 7 8 9 10
16 17 18 19 20 21 22 23 24 25
11 12 13 14 15
26 27 28 29 30
TGF-j1 -negative cases
31 32 33 34 35 36 37 38 39 40 41 42
TGF-j1
P-actin
Figure 1 Expression of TGF-fl in 42 advanced gastric carcinoma specimens
Reverse transcriptase-polymerase chain reaction
(RT-PCR) and gel electrophoresis
Total RNA from each biopsy specimen was isolated by sinole-
step. guanidium thiocvanate-phenol-chloroform extraction
(Chromczynski and Sacchi. 1987). Biopsy specimens were minced
on ice and homogenized manually in lysis buffer. The RNA frac-
tion was suspended in diethyl pyrocarbonate-treated water and
quantitated by absorbance at 260 nm. RT-PCR was carried out
according to the Perkin-Elmer/Cetus protocol for reverse tran-
scription of RNA and amplification of cDNA. The RT reaction
was carried out with 0.5 ).tg of RNA per sample. cDNA amplifica-
tion for j-actin was performed for 30 cycles with annealing
temperature of 58CC. cDNA amplification for TGF-,B1 was
performed for 28 cycles with annealing temperatures of 65°C.
Primer sequences were as follows. S-actin: 5'-GTG GGG CGC
CCC AGG CAC CA-3'. 5'-CTC CT( AAT GTC ACG CAC GAT
TTC-3' (Albino et al. 1991): TGF-41: 5'-AAG TGG ATC CAC
GAG CCC AA-3'. 5'-GCT GCA ClT GCA GGA GCG CA-3'
(Derynck et al. 1985). Aliquots ofthe PCR products (7.5 gl) were
separated and visualized w-ith ethidium bromide staining after
electrophoresis on a 1.5%i agarose gel in Tris acetate EDTA buffer
at 100 V for 20 min. RT-PCR was performed immediately after
sample collection by the same investigator. without knowledge of
the corresponding clinical data. Identification of the PCR product
specific for TGF-[1 mRNA (positivity) was performed by two
investigators.
Table 1 Relationship between the expression ofTGF-p1 mRNA and the
pathological parameters in 42 patients with advanced gastric carcinoma
TGF-j1 (-) TGF-f1 (+) P-value
Age 61.6 -16.5 61.6± 14.2 0.9957
Sex
Male 9 20 0.7225
Female 3 10
Stage
5 0
11 4 5 < 0.001
III 3 15
IV 0 10
Depth of invasion
t2 6 8
t3 6 19 0.1016
t4 0 3
Nodal status
Nodal negative 8 5 0.0030
Nodal positive 4 25
Histological type
Well differentiated 2 2
Moderatey differentiated 5 8
Poorly differentiated 4 16 0.5451
Signet ring cell 0 2
Mucinous 1 2
PCR product verification by Southern blot
PCR products were transferred to nylon membranes and probed
with a radiolabelled oligonucleotide complementary to sequences
within the region flanked by the primers. The blots were
hybridized at 50CC with probes labelled on their 5' end with y- 'P
([y-]'PATP: 7000 Ci m-t-: ICN Pharmaceuticals. Costa Mesa.
CA. USA) and T4 pol> nucleotide kinase (Pharmacia. Uppsala.
Sweden) for 18 h. The membranes were washed for 10 min
with 2 x standard saline citrate (SSC) and 0.1%7r sodium dodecvl
sulphate (SDS). followed by 0.2 x SSC and 0.1%c SDS at ambient
temperature. then subjected to autoradiographN.
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Figure 2 Overall survival curves of the 42 patients with advanced-stage
gastric carcinoma, according to the expression of TGF-1l mRNA in the
carcir*rna specimens. The P-value was determined using the log-rank test
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Figure 3 Overall survival curves of the 32 patients with advanced gastric
carcinora patients who underwent a curative resection. The P-value was
determined using the log-rank test
Table 2 Risk factors affecting survival rate by mulftivariate analysts in the 42
patients with advanced gastnc carciworna
Parameter Hazardsratio P-value
Serosal invasion
Negative vs positive 3.766 0.0476
Lymph node metastasis
Negative vs positive 1.533 0.5545
Lymphatic invasion
Negative vs positve 2.137 0.4010
Venous invasion
Negative vs positive 0.773 0.6155
Histological type
Intestinal vs diffuse 0.545 0.2258
Expression ofTGF-01 mRNA
Negative vs positive 12.598 0.0186
Intestinal type: well-differentiated, moderatety differentiated and mucinous
adenocarcinoma. DifFuse type: poorty differentiated adenocarcinoma and
signet ring cell carcinorna.
Statistics
Chi-square test and Mann-AWhitneys Ls-test w-ere used for statis-
tical analyses between mRNA expression for TGF-PI and tradi-
tional clinical and pathological parameters. Survival curves were
calculated using the Kaplan-Meier method and analysed using the
log-rank test. The influence of each variable on overall survival
was assessed by Cox's proportional hazard model. Calculations
were carried out using Stat View (Abacus Concepts. Berkeley. CA.
USA). A P-value < 0.05 was considered to be significant.
RESULTS
Of the 42 patients examined. 12 TGF-[l-negative cases) had no
visible PCR products specific forTGF-5l mRNA. while 30 (TGF-
Pl-positive cases) had a sharply visible PCR product (Figure 1).
The correlations between expression ofTGF-PI mRNA and clini-
copathological parameters are shown in Table 1. Significant corre-
lations were found betweenTGF-. 1 mRNA expression and tumour
stage (P < 0.0001). as well as nodal inxolvement (P = 0.0030). The
prognosis ofthe TGF-1I-positive group was worse than that ofthe
Table 3 Relabonship between the expression of TGF-(1 mRNA and the
path<olgical parameters in 32 patients with advanced gastnc carcinoma who
underwent curative resection
TGF41(-) TGF-1 (+) P-value
Age 61.5+ 16.5 61.1 ± 13.2 0.9312
Sex
Male 9 14 > 0.999
Female 3 6
Stage
5 0
11 4 5 0.0015
III 3 14
IV 0 1
Depth of invasion
t2 6 5 0.1560
t3 6 15
Nodal status
Nodal negative 8 3 0.0060
Nodal positive 4 17
Histolkgical type
Well differentiated 2 1
Moderately differentiated 5 5
Poorly differentiated 4 10 0.4849
Signet nng cell 0 2
Mucinous 1 2
TGF-Pl-negative group (P = 0.0014) (Figure 2). Multivariate
analysis indicated that TGF-,B1 mRNA expression (P = 0.0186)
was a significant independent prognostic factor (Table 2). The
prognosis of the 32 advanced carcinoma patients w%ho underwent
curative resection was studied. Overall survival of the 20 TGF-41-
positixe patients was worse than that of the 12 TGF-01-negative
patients (P = 0.0048) (Figure 3). Significant correlations were
found between TGF-,B1 mRNA expression and both stage (P =
0.0015) and nodal involvement (P = 0.0060) (Table 3). Multivariate
analvsis also demonstrated that only TGF-f1 mRNA expressio
(P = 0.0306) was an independent prognostic factor (Table 4).
Ten patients underwent non-curatixe resection because of peri-
toneal dissemination (four cases). hepatic metastasis (five cases)
or oxarian metastasis (one case) (Table 5). All of these carcinoma
specimens expressed TGF-4 1 mRNA.
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Table 4 Risk factors affecting survival rate by muttivariate analysis in the 32
patients with advanced gastnc carcinoma who underwent curative resecton
Parameter Hazards ratio P-value
Serosal invasion
Negative vs positive 4.578 0.0770
Lymph node metastasis
Negative vs positive 1.872 0.4931
Lymphatic invasion
Negative vs positive 1.632 0.6916
Venous invasion
Negative vs positive 0.905 0.8820
Histological type
Intestinal vs diffuse 0.331 0.1180
Expression of TGF-)1 mRNA
Negative vs positive 11.043 0.0306
Intestinal type: well-differentiated, moderately differentiated and mucinous
adenocarcinoma. Diffuse type: poorty differentiated adenocarcinoma and
signet ring cell carcinoma.
DISCUSSION
We have demonstrated that TGF-, 1 mRNA expression in biopsied
carcinoma specimens is a potent preoperative prognostic indicator
independent of clinicopathological parameters in advanced-stace
gastric carcinomas.
Current therapeutic stratecies for individual patients with gastric
carcinoma are generally determined by the stage ofdisease at post-
operative pathological examination.,which is especially affected by
the presence and grade of involved rerional lymph nodes.
Therapeutic strategies determined by preoperative assessment of
nodal insvolsement may improve the survival rate. We have demon-
strated previously that TGF- 1 mRNA expression showed a posi-
tive correlation wvith nodal involhement in advanced carcinomas
(Nakamura et al. 1997). In the present study. TGF-P1 mRNA
expression similarly showed a positise correlation with lymph node
disease. In addition. the TGF-Pl-positive patient had a shorter
overall survival compared s ith TGF-P1-negative patients who
underwent gastrectomrv or curative resection. Although we hypoth-
esized that poor prognosis in TGF-1 positive cases resulted from
lymph node involvement. multisariate analvsis indicated that tran-
scnption ofTGF-11. not nodal status. was a prognostic factor. This
findinc may explain why tumours recur in some patients without
nodal involvement. One possibility is that TGF-51 mRNA levels in
carcinoma specimens may predict lymph node metastasis. esen
whenconsentional histological examination is necative (Hayashi et
al. 1995: Maehara et al. 1996). Another is that the determination of
TGF-J31 mRNA may be independent ofthe traditional pathological
characteristics predicting, sunival.
TGF-P is a prototype of multifunctional growsth factors that
either inhibit or stimulate cell proliferation (Mackay et al. 1995).
In vitro studies using cell lines have demonstrated that TGF-1
inhibits the growth of most epithelial cells (Masui et al. 1986:
Shipley et al. 1986: Coffey et al. 1988: Moses et al. 1990).
includinc, colon carcinoma (Hoosein et al. 1987) and gastric carci-
noma (Ito et al. 1992). Little is knoswn. however. about the associ-
ation of TGF-3 with progression of malignant diseases in svisvo.
Recent observations have demonstrated that TGF-3 may facilitate
tumour growth through immunosuppression. angiogenesis or
changes in the extracellular matrix (Pepper et al. 1990: Kehrl et al.
1991: Tada et al. 1991: Ueki et al. 1992) Several studies have
demonstrated high levels ofTGF-PI mRNA in gastric carcinoma
(Tahara. 1990: Hiravama et al. 1992). especially the scirrhous type
(Yoshida et al. 1989). We have previously examined TGF-11
mRNA in surgically resected primary gastric carcinomas
(Morisaki et al. 1996). We have reported that TGF-41 mRNA was
frequently expressed in poorly differentiated adenocarcinomas and
in tumours wvith an advanced stage or lvmph node spread
(Morisaki et al. 1996). An association betw-een TGF-11 mRNA
expression with metastatic spread to axillary lymph nodes has
been shown in breast cancer (Walker and Dearina. 1992).
Tsushima and colleagues (1996) have reported that TGF-11
expression may be associated s ith colorectal adenocarcinoma
invasiveness (Tsushima et al. 1996.) Friess and colleagues (1993)
have demonstrated that human pancreatic cancers have increased
levels of TGF-, isoforms and suggested that TGF-3 may
contribute to disease progression (Friess et al. 1993).
We suggest that investigation of TGF- 1 mRNA in carcinoma
specimens may be a new tool for the preoperative evaluation ofthe
aggressise potential of gyastric carcinoma. The present study
showed a significant correlation bettween expression of TGF-11
mRNA in castric carcinoma specimens and a poor prognosis.
Similar results have been reported in other types of solid tumours.
Takanami and colleagues (1994) have demonstrated that TGF-I1
was an independent prognostic indicator in patients with
pulmonary adenocarcinoma (Takanami et al. 1994). Gorsch and
colleagues (1992) described an association between the intensity
of TGF-31 immunoreactisity in breast carcinoma specimens and
disease-free survival that was independent of established prog-
nostic variables (Gorsch et al. 1992).
Table 5 Ten patients with advanced gastnc carcinoma who underwent non-curative resection
Patient no. Reasons for non-curative resection Expression ofTGF-31 mRNA Outcome
1 Peritoneal dissemination Positive 3 M Dead
2 Peritoneal dissemination Positive 5 M Dead
3 Peritoneal dissemination Positive 8 M Dead
4 Peritonea] dissemination Positive 15 M Alive
5 Hepatic metastasis Positive 1 M Dead
6 Hepatic metastasis Positive 1 M Dead
7 Hepatic metastasis Positive 5 M Dead
8 Hepatic metastasis Positive 9 M Dead
9 Hepatic metastasis Positive 25 M Alive
10 Ovarian metastasis Positive 4 M Dead
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Because TGF-11 mRNA may be elevated in normal tissue adja-
cent to tumour tissue (Anzano et al, 1985; Travers et al, 1988;
Gomella et al, 1989). it remains unclear whethergastric carcinoma
cells are the main source ofTGF-5l in our study. We have shown
that TGF-]1 mRNA was expressed more frequently in carcinoma
tissues than in adjacent normal cells (Morisaki et al, 1996). We
confirmed thatTGF-01 protein was expressed in the tumour cells
of five TGF-j1-positive carcinoma specimens determined by RT-
PCR (data not shown). We postulate that TGF-I1 produced by
gastric carcinoma cells may act as a growth factor for the tumour
through autocrine and paracrine loops.
TGF-0 action is tightly regulated through transcriptional control
(Kim et al, 1989a and b). It is possible that highly malignant carci-
nomas lose the inhibitory response toTGF-(1 (Torre-amione et al,
1990; Welch et al, 1990; Gorsch et al, 1992; Eklov et al, 1993;
Glick et al, 1993; Jirtle et al, 1993; Cui et al, 1994). Some carci-
noma cells may escape negative regulation by TGF-0 through
post-transcriptional down-regulation ofTGF-0production (Fowlis
et al, 1992; Cui et al, 1994). Other carcinomas may escape at the
receptor (Kimchi et al, 1988) or post-receptor level (Braun et al,
1990; Laiho et al, 1990; Pietenpol et al; 1990; Ito et al, 1992). It is
also possible that autocrine or paracrine stimulation ofcarcinoma
cell proliferation by TGF-5l maydirectly influence progression of
gastric carcinoma. Leof and colleagues (1986) have demonstrated
a positive growth response toTGF-01 (Leofet al, 1986).
TGF-01 mRNA expression significantly correlated with the
presence of involved lymph nodes. Extended gastrectomy
including D3 or D4 lymph node dissection may be recommended
for improved survival inTGF-0l-positive cases.
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